产品名称
VPC 32183 (S), Avanti Research™ - A Croda Brand 857340P, powder
assay
>99% (TLC)
form
powder
packaging
pkg of 1 × 1 mg (857340P-1mg), pkg of 1 × 10 mg (857340P-10mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand 857340P
lipid type
cardiolipins
phospholipids
shipped in
dry ice
storage temp.
−20°C
SMILES string
O=C(CCCCCCC/C=C\CCCCCCCC)N[C@H](COP(O)([O-])=O)CC1=CC=C(OCC2=CC=CC=N2)C=C1.[NH4+]
General description
VPC 32183 (S) acts as a lysophosphatidic acid (LPA)1/3 receptor antagonist.
VPC 32183(S) is a competitive antagonist at the LPA1 and LPA3 receptors. VPC 32183 is devoid of agonist activity at the human LPA1, LPA2 and LPA3 receptors, and, presumably, at other mammalian LPA receptors.
Application
VPC 32183 (S) has been used to study classical G protein coupled receptor (GPCR) activation signature in a lysophosphatidic acid (LPA)-type agonist bound LPA1. It has also been used as an LPA1/3 inhibitor to elucidate the LPA3 receptor′s ability to increase viability among melanoma cells.
Packaging
5 mL Amber Glass Screw Cap Vial (857340P-10mg)
5 mL Amber Glass Screw Cap Vial (857340P-1mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
存储类别
13 - Non Combustible Solids
wgk
WGK 3
法规信息
新产品
此项目有
Glycerophospholipids in the Brain: Phospholipases A2 in Neurological Disorders (2006)
Lys39-lysophosphatidate carbonyl oxygen interaction locks LPA 1 N-terminal cap to the orthosteric site and partners Arg124 during receptor activation
Omotuyi OI, et al.
Scientific Reports, 5, 13343-13343 (2015)
The Src homology 3 binding domain is required for lysophosphatidic acid 3 receptor-mediated cellular viability in melanoma cells
Jia W, et al.
Cancer letters, 356(2), 589-596 (2015)
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 857340P-1MG | 04061835186181 |
| 857340P-10MG | 04061835186174 |